Mar 01, 2021 / 04:00PM GMT
Joseph John-Charles Thome - Cowen and Company, LLC, Research Division - VP of Healthcare
Hi, everyone, and thank you for joining us at our Cowen health care conference this year.
It is my pleasure to have with me today Dr. Herriot Tabuteau, CEO of Axsome Therapeutics.
Thank you very much for taking the time to join us today.
Maybe first, congratulations on all the progress that's happened over 2020. If you want to just outline maybe some of the key takeaways over the past 6 to 12 months and what we should be looking for over the course of 2021.
Herriot Tabuteau - Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President
Well, first of all, Joe, thanks for having us at the Cowen health care conference.
So I'd say, if you look back to last year, it was a year when we focused on executing to make sure that we got to a point whereby we could file our NDA. So we had a lot of regulatory interactions. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder, AXS-07 in the
Axsome Therapeutics Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers